Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Perspective: preventive isoniazid therapy and the liver.

H L Israel1, J E Gottlieb, W C Maddrey

  • 1Department of Medicine, Jefferson Medical College of Thomas Jefferson University, Philadelphia.

Chest
|May 1, 1992
PubMed
Summary

Preventive isoniazid (INH) therapy carries a risk of fatal hepatitis, especially for those with low tuberculosis risk. Recommendations for widespread INH use should be restricted due to these serious risks.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Severe hepatitis from methyldopa.

Gastroenterology·2012
Same author

Chronic pulmonary coccidiomycosis.

Transactions & studies of the College of Physicians of Philadelphia·2010
Same author

Acute respiratory distress syndrome due to pulmonary involvement by neoplastic plasma cells in multiple myeloma.

Thorax·2006
Same author

The relationship between the angle of the tibial tunnel in the coronal plane and loss of flexion and anterior laxity after anterior cruciate ligament reconstruction.

The American journal of sports medicine·2001
Same author

Documenting and comparing medical students' clinical experiences.

JAMA·2001
Same author

Adult hepatitis B vaccination using a novel triple antigen recombinant vaccine.

Hepatology (Baltimore, Md.)·2001

Area of Science:

  • Public Health
  • Infectious Disease Epidemiology
  • Pharmacovigilance

Background:

  • The preventive use of isoniazid (INH) for tuberculosis (TB) has been debated since 1975, with ongoing advocacy by official agencies despite conflicting cost-effectiveness and risk-benefit analyses.
  • Previous studies on INH prophylaxis show a trend towards downplaying its hepatotoxicity and overlooking the decrease in TB incidence and mortality in regions without widespread INH adoption.

Observation:

  • This review highlights three fatal cases of isoniazid-associated hepatitis, underscoring that this severe complication remains a significant concern with preventive INH use.
  • The risk-benefit profile is unfavorable for compliant adults and older children with low TB risk, who are exposed to potentially fatal hepatitis.
  • Conversely, INH therapy is challenging to administer effectively to high-risk populations such as individuals with alcohol or drug addiction.

Related Experiment Videos

Findings:

  • Current widespread recommendations for preventive INH therapy are deemed unwise due to the disproportionate risk of fatal hepatitis.
  • The study challenges the minimization of INH hepatotoxicity in risk-benefit assessments.
  • There's a critical need to re-evaluate the declining TB rates in non-prophylaxis countries.

Implications:

  • Health departments and medical practitioners should significantly limit the prescription of preventive INH therapy.
  • A reassessment of current TB prevention strategies focusing on targeted, high-risk groups is warranted.
  • The findings necessitate a more cautious approach to INH prophylaxis, prioritizing patient safety and addressing the actual burden of disease.